SA
Sai Parenterals Ltd (SAIPARENT)
₹492.30
Mkt cap
₹2,175 Cr
P/E ratio
87.20
P/B
4.40
Div yield
0.00%
ROE
4.88%
ROCE
5.28%
EPS (TTM)
₹5.65
Book value
₹112
52W range
400–706
Sector
Healthcare
Price history
Previous close
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing. [1]
NSE SAIPARENTBSE 544742
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthHigh
TechnicalsNeutral
52-week range
−30.27% from high₹492
₹400+23.07% from low₹706
Current
₹492.30
Prev close
₹495.40
Day
−0.63%
Price performance
1D
−1.68%
1W
−1.96%
1M
+7.88%
3M
−10.36%
6M
+1.46%
1Y
—
YTD
+21.35%
Financials
Revenue, profit & margin
P/E ratio
87.2×
SAIPARENT is 169% above the sector median of 32.5×
SAIPARENT87.2×
Sector median32.5×
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|
| Sales | 33 | 54 | 96 | 198 | 179 | 195 | |
| YoY Sales growth | +435% | +264% | |||||
| Expenses | 29 | 42 | 100 | 172 | 155 | 155 | |
| Operating Profit | 5 | 11 | -4 | 26 | 24 | 40 | |
| OPM % | 14% | 21% | -3.7% | 13% | 13% | 21% | |
| Other Income | 1 | 1 | 3 | 3 | 4 | 4 | |
| Interest | 2 | 2 | 5 | 8 | 9 | 9 | |
| Depreciation | 1 | 1 | 6 | 8 | 8 | 25 | |
| Profit before tax | 2 | 9 | -12 | 12 | 10 | 10 | |
| Tax % | 30% | 31% | -43% | -6% | 19% | -6% | |
| Net Profit | 1 | 6 | -7 | 13 | 8 | 11 | |
| EPS in Rs | 0.38 | 1.72 | -1.80 | 2.98 | 1.79 | 2.38 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202651.16%Promoter
Promoters51.16%
FIIs2.85%1.18
DIIs7.83%0.69
Public38.16%1.87
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.76 | 4,52,251 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.16 | 1,78,374 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.53 | 1,23,980 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.42 | 1,19,700 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.47 | 1,16,119 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.81 | 1,14,316 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Sai Parenteral's | ₹492.30 | 87.24 | 2,175 | 0.00% | 11 | +65.51% | 195 | +264.13% | 5.28% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,983 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports1
Concall transcripts8
Credit ratings1
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 17 Nov - Subsidiary SP Analytics to acquire majority stake in Bion Therapeutics’ prescription business by month-end.Board Meeting Outcome for Outcome Of Board Meeting Held On Monday, 16Th November, 2026 16 Nov - Sai Parenterals to acquire majority stake in Bion Therapeutics via SP Analytics by 30 Nov 2026.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 7 Nov - Call conducted on Monday the 2nd day of November, 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Nov - Un-audited financial results for the quarter and half-year ended 30th September, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 2 Nov - Audio recording of Q2 FY2027 earnings call held on 2 November 2026 is now available.






